Johnson & Johnson announces ERLEADA provided overall survival benefit

Johnson & Johnson announced the results of a real-world, head-to-head study showing that ERLEADA provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer, mCSPC. Presented at the 6th European Congress of Oncology Pharmacy, ECOP, in Lisbon, Portugal, on October 2, this study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors, ARPIs, in mCSPC. The analysis demonstrated patients with mCSPC who initiated ERLEADA as their first ARPI had a statistically significant 23 percent reduction in their risk of death at 24 months compared to patients who initiated on enzalutamide. The proportion of patients alive at 24 months observed in the ERLEADA cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial. TITAN demonstrated a statistically significant superior overall survival benefit of ERLEADA plus androgen deprivation therapy compared to ADT alone at the primary analysis after a median 22.7 months of follow-up and at the final analysis after a median 44 months of follow-up.